Destiny Pharma to join panel discussion at LSX

RNS Number : 6222N

Destiny Pharma PLC

02 February 2021

 

Destiny Pharma PLC

("Destiny" or "the Company")

Destiny Pharma to Participate in Panel Discussion at the

7^th Annual LSX World Congress 2021

Brighton, UK, 2 February 2021  - Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces that Neil Clark, Chief Executive Officer, will be taking part in a panel discussion at the 7^th Annual LSX World Congress to be held virtually between 1-5 February, 2021.

The panel discussion 'Investing In Infectious Disease - How Will The Covid Pandemic Transform The Development, Commercialisation, And Partnering Landscape?' will be held at 15:00 GMT on 2^nd February 2021.

The panel will be made available through the conference website and will be available to registered participants throughout the event -  www.lsxleaders.com/lsx-world-congress .

-  Ends -

Enquiries:

Destiny Pharma plc

[phone]

Neil Clark (Chief Executive Officer)

Shaun Claydon (Chief Financial Officer and Company Secretary)

finnCap Limited - Nominated Adviser and Joint Broker

[phone]

Geoff Nash / Kate Bannatyne / Charlie Beeson (Corporate Finance)

Alice Lane (ECM)

WG Partners LLP - Joint Broker

[phone]

Nigel Barnes / Claes Spång / Nigel Birks / Andrew Craig

Optimum Strategic Communication

[phone]

Mary Clark / Shabnam Bashir / Manel Mateus

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is in a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

For further information, please visit https://www.destinypharma.com

 

END

 

 

NRAFLFERFAILIIL